Skip to main content
. Author manuscript; available in PMC: 2020 Jul 1.
Published in final edited form as: Antiviral Res. 2019 Apr 7;167:25–34. doi: 10.1016/j.antiviral.2019.04.004

Figure 6. Prophylactic and therapeutic efficacy of BDGR-4 in BALB/c mice challenged with VEEV TrD.

Figure 6.

Groups of eight BALB/c mice per treatment, vehicle, or BDGR-4 at 25 mg/kg/day, were assessed for (A) survival and (B) morbidity over 24 days following a s.c. challenge with 10LD50 VEEV TrD. (C) Four additional mice were used to determine the VEEV TrD titer by plaque assay on day 4. (D) All dosing was BID for a total of 8 days and delivered by i.p. with compound formulated in 25%PEG400/10%RH40/65%Water. Prophylactic doses started at 2 hours prior to virus challenge and therapeutic doses started at 24 or 48 hpi.